A patient sits through the consultation, agrees with everything, and then says they need to think about it. Frequently what they are thinking about is not whether the treatment works. It is whether they can produce $22,000 in the next two weeks. Clinics that treat financing as a back-office detail lose those patients quietly.
Patient financing turns a lump-sum decision into a monthly one, and in cash-pay regenerative medicine it materially changes close rate. It should be introduced as part of the price conversation, not offered as a rescue after the patient hesitates.
The Real Objection Behind "Let Me Think About It"
Price objections in this category are usually liquidity objections. The patient is not disputing the value; they are looking at a number that has to come from savings, a home equity line, or nowhere.
That distinction matters because the two require opposite responses. A value objection needs more evidence. A liquidity objection needs a payment structure. Answering a liquidity objection with more clinical proof leaves the patient exactly where they were.
Learning to tell them apart is a coordinator skill worth training deliberately, and it is covered alongside other stalls in top stem cell consultation mistakes.
Introduce Financing Before the Objection
The most common mistake is holding financing back as a save. By the time it is offered, the patient has already mentally declined and is looking for an exit.
Present it as part of how the program is priced. State the total, then immediately state the monthly equivalent. "The program is $22,000, which most patients structure at around $420 a month." The patient now evaluates a monthly figure against their budget rather than a lump sum against their savings.
This is not a discount and should never be framed as one. The price has not changed. What changed is the shape of the decision.
What to Look for in a Financing Partner
Approval rates in this category. Elective medical lenders vary widely, and a partner who declines most of your patients creates a worse experience than not offering financing at all.
Tiered options. A single lender serves one credit band. Two or three, covering strong and subprime applicants, dramatically increases the share of patients who find a workable path.
Speed. Approval should happen during the consultation. A decision that takes days gives the moment away, and momentum in this category decays quickly.
Clear economics. Understand the merchant fee on each plan. A plan costing eight percent changes your effective case value, and that belongs in your pricing math rather than as a surprise later.
Train the Team to Present It Cleanly
Coordinators are often uncomfortable with financing because it feels like discussing someone's money troubles. That discomfort transmits and makes the patient uncomfortable too.
Normalize it. Financing is how most people pay for significant elective care, and saying so plainly removes the stigma. "Most of our patients use financing" is a true and useful sentence.
Have the team know approximate monthly figures for common program values without reaching for a calculator, and be able to walk a patient through application in a few minutes on a tablet in the room. Fluency here is worth more than any script.
Deposits Do Different Work
Financing solves affordability. A deposit solves commitment, and they are not interchangeable.
A modest deposit at the moment of decision converts intention into schedule. It reduces the drift where a patient agrees enthusiastically and never books. Clinics that take a deposit at close see materially better show rates for treatment.
Keep the deposit policy simple, stated up front, and consistent. Improvised terms invented per patient create confusion and the sense that everything is negotiable, which invites further negotiation on price.
Where This Fits in the Sales Conversation
The sequence that works: establish candidacy, present the protocol, state the price, present the monthly structure, then ask for the decision.
Note that price comes before financing and both come before the ask. Patients who hear a monthly figure without a total feel they are being handled. Patients who hear the total with no structure feel the number is impossible. The pairing is what makes it land, and it aligns with the approach in stem cell clinic pricing strategy.
Measure the Effect
Track what share of closed patients used financing, approval rate by lender, and close rate for patients offered financing versus not. Most clinics that measure this find financing is involved in a large share of their revenue and had been treating it as an afterthought.
Also track it in your case value math. If a meaningful percentage of cases carry a merchant fee, your true average case value is lower than your list pricing suggests, which affects the acquisition cost ceiling in patient acquisition cost for stem cell clinics.
Frequently Asked Questions
Does offering financing attract lower-quality patients?
It attracts patients who have the intent but not the liquidity, which is a different thing from low quality. Qualification should still happen on clinical candidacy and genuine interest, not on apparent ability to pay in full.
Should we offer in-house payment plans instead?
In-house plans keep the merchant fee but move collection risk onto the clinic and create an accounts-receivable function most clinics are not equipped to run. Third-party financing pays you in full and absorbs the default risk, which is usually the better trade.
How many lenders should we work with?
Two or three, covering different credit tiers. One lender leaves a large share of patients without an option; more than three creates confusion for coordinators and slows the conversation.
When exactly should financing come up?
Immediately after stating the total price, in the same breath. Waiting until the patient objects converts it from a normal option into a concession.